On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co.

Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...

Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...

But does this mean a rally in Eli Lilly is likely to continue? Below, I’ll discuss essential points from the earnings report and management ... on a daily basis. Our team has identified the ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. Here are two important insights from that call that should excite investors about ...

In total, 234 investments creating 13,500 new jobs over the next five years, 59% of which were in regional locations ...

it’s about as confident tone as you can expect from or as you’d want from a management team,” said Kevin Gade, chief operating officer at Bahl & Gaynor, which owns Lilly’s shares. Eli ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...